Session » Poster Session 1

The 2020 Pediatric Rheumatology Symposium, originally scheduled for April 29 – May 2, was postponed due to COVID-19; therefore, abstracts were not presented as scheduled.

Date: Thursday, April 30, 2020

Time: 6:00PM-7:00PM

Meeting: 2020 Pediatric Rheumatology Symposium

6:00PM-7:00PM: Abstract Number: 053

Acceptability and Usability Testing of a Preliminary Version of the JIA Option Map, an Electronic Decision Aid for Pain Management Options in Juvenile Idiopathic Arthritis

6:00PM-7:00PM: Abstract Number: 169

Addressing the Pediatric Rheumatology Workforce Shortage: Is Early Exposure Enough?

6:00PM-7:00PM: Abstract Number: 072

Allogenic Hematopoietic Stem Cell Transplantation for Refractory Childhood Rheumatic Diseases

6:00PM-7:00PM: Abstract Number: 041

Ancestry, Demographic and Clinical Features of Israeli Periodic Fever Aphthous Stomatitis, Pharyngitis and Adenitis (PFAPA) Syndrome – a Multi-center Cohort

6:00PM-7:00PM: Abstract Number: 066

Baseline Kidney Biopsy in Lupus Patients Without Renal Manifestations. Underappreciated or Overrated?

6:00PM-7:00PM: Abstract Number: 059

Challenges Faced by Families of Children with an Auto-inflammatory Disease

6:00PM-7:00PM: Abstract Number: 054

Clinical and Laboratory Characteristics in Juvenile-onset Systemic Lupus Erythematosus Across Age Groups

6:00PM-7:00PM: Abstract Number: 170

Clinical Team Perspectives on the Transition from Pediatric to Adult Care for Patients with Childhood-Onset SLE

6:00PM-7:00PM: Abstract Number: 171

Development and Acceptability of an Adolescent Self-management Program for Juvenile Idiopathic Arthritis

6:00PM-7:00PM: Abstract Number: 068

Development of CARRA Consensus Treatment Plans for Severe ANCA-associated Vasculitis – Final CARRA-wide Consensus

6:00PM-7:00PM: Abstract Number: 151

Differences in Chromatin Architecture Between Treatment-Naïve Pediatric and Adult Lupus Patients

6:00PM-7:00PM: Abstract Number: 073

Differences in Clinical Presentation Between Israeli and United States Children with Juvenile Spondyloarthritis

6:00PM-7:00PM: Abstract Number: 055

Differential Analysis of Serum and Urine S100 Proteins in Juvenile-onset Systemic Lupus Erythematosus (jSLE)

6:00PM-7:00PM: Abstract Number: 153

Double Negative T Cells in Juvenile Dermatomyositis

6:00PM-7:00PM: Abstract Number: 074

Establishment of a Registry for Juvenile Idiopathic Arthritis (JIA) Patients in South Australia (SA): Focus on Patient Reported Outcome Measures (PROMs) and Experiences (PREMs)

6:00PM-7:00PM: Abstract Number: 152

Hemophagocytic Lymphohistiocytosis (HLH) Genetic Variants in Childhood-onset SLE (cSLE) with Macrophage Activation Syndrome (MAS)

6:00PM-7:00PM: Abstract Number: 076

How Do Pediatric Rheumatologists Diagnose Macrophage Activation Syndrome in Systemic Onset Juvenile Idiopathic Arthritis? An Examination of the CARRA Registry

6:00PM-7:00PM: Abstract Number: 173

Impact of a Nutrition-Focused Quality Improvement Intervention on Hospital Readmission Rates in Henoch-Schönlein Purpura with Gastrointestinal Involvement

6:00PM-7:00PM: Abstract Number: 172

Improved Self-efficacy and Knowledge in Pediatric Rheumatology Among General Pediatric Residents Following the Introduction of a Standardized Teaching Series

6:00PM-7:00PM: Abstract Number: 062

Is Positron Emission Tomography/Magnetic Resonance Imaging (PET/MRI) a Reliable Tool for Detecting Vascular Activity in Treated Childhood-Onset Takayasu’s Arteritis (C-TA)? A Multicenter Study

6:00PM-7:00PM: Abstract Number: 058

Kawasaki Disease in Ontario Children from 1995-2017: A Population-based Descriptive Analysis

6:00PM-7:00PM: Abstract Number: 049

Levels of Anxiety and Depressive Symptoms in Juvenile Idiopathic Arthritis (JIA) and Their Correlation to Disease Manifestations Using Patient-Reported Outcomes Measurement Information System (PROMIS®) Measures

6:00PM-7:00PM: Abstract Number: 050

Long Term Safety of Biologics and Biosimilars in Pediatric Rheumatic Diseases: An Experience from a Single North Indian Centre

6:00PM-7:00PM: Abstract Number: 149

Low C4 Copy Number of Total C4 Gene, C4B Gene and C4BL Gene in Children with Pediatric Acute-onset Neuropsychiatric Syndrome (PANS)

6:00PM-7:00PM: Abstract Number: 063

Musculoskeletal Ultrasound Assessment in Pediatric Knee Hypermobility

6:00PM-7:00PM: Abstract Number: 044

Nailing Down Nailfold Capillaroscopy Practices: A Survey of Pediatric Rheumatologists Within the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Network

6:00PM-7:00PM: Abstract Number: 052

Nasopharyngeal Pneumococcus Colonization in Patients with Childhood Onset Systemic Lupus Erythematosus (cSLE) Compared to Healthy Controls

6:00PM-7:00PM: Abstract Number: 046

Near Infrared Indocyanine Green Imaging Reveals Altered Anatomy and Diminished Function in Lymphatic Vessels in the Hands of Rheumatoid Arthritis Patients During Flare

6:00PM-7:00PM: Abstract Number: 045

No-Shows: a Search for Modifiable Risk Factors

6:00PM-7:00PM: Abstract Number: 056

Non-criteria Antiphospholipid Antibodies Associated with Pediatric Rheumatic Disease: A Single-Center Case Series

6:00PM-7:00PM: Abstract Number: 048

Novel Algorithm to Increase Sensitivity of Detecting Active Arthritis in Children Through Infrared Thermal Imaging

6:00PM-7:00PM: Abstract Number: 060

Parsing Apart the Pain Experience: Exploring Treatment-Related Pain in Juvenile Idiopathic Arthritis

6:00PM-7:00PM: Abstract Number: 071

Patient Reported Outcomes and Resilience in Pediatric Systemic Lupus Erythematosus

6:00PM-7:00PM: Abstract Number: 047

Patients with Juvenile Idiopathic Arthritis in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry: Clinical Characteristics and Inception Cohorts

6:00PM-7:00PM: Abstract Number: 051

Pediatric Providers’ Perspectives on Suspected Immune-Mediated Diffuse Alveolar Hemorrhage and Clinical Care Pathways

6:00PM-7:00PM: Abstract Number: 061

Perspectives of Radiologist Physicians in the Imaging of Chronic Nonbacterial Osteomyelitis

6:00PM-7:00PM: Abstract Number: 065

Prosthetic Temporomandibular Joint Replacement in a Cohort of Adolescent Patients with Juvenile Idiopathic Arthritis

6:00PM-7:00PM: Abstract Number: 075

Pseudotumor Cerebri Syndrome in Children with Systemic Lupus Erythematosus

6:00PM-7:00PM: Abstract Number: 043

Resolution of Coronary Artery Changes in Patients with Refractory Kawasaki Disease with Prolonged Course of Infliximab: A Case Series

6:00PM-7:00PM: Abstract Number: 067

Response to Treatment with Intra-articular Triamcinolone Hexacetonide and Triamcinolone Acetonide in Oligo-articular Juvenile Idiopathic Arthritis

6:00PM-7:00PM: Abstract Number: 069

Rheumatic Fever in a Tertiary Medical Center – 25 Years of Follow Up

6:00PM-7:00PM: Abstract Number: 042

Safety Analysis of Infliximab-dyyb as Compared to Infliximab in Pediatric Rheumatic Conditions

6:00PM-7:00PM: Abstract Number: 064

The First 18 Months of a Pediatric Rheumatology Service at a Tertiary Referral Hospital in Kenya

6:00PM-7:00PM: Abstract Number: 070

The Importance of the Patient Global Health Assessment of Disease Activity in Polyarticular Juvenile Idiopathic Arthritis

6:00PM-7:00PM: Abstract Number: 150

The Killer Immunoglobulin-like Receptor KIR3DL1 in Combination with HLA-Bw4 Is Associated with Pediatric Acute-onset Neuropsychiatric Syndrome (PANS)

6:00PM-7:00PM: Abstract Number: 057

Transition from Pediatric to Adult Rheumatology: The Clinician as a Fundamental Ally

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].